n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, April 5th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Sector 5, Inc. (SFIV)

We are reporting on Sector 5, Inc. (SFIV) today, here at the QualityStocks Daily Newsletter.

Sector 5, Inc. sells, manufactures, and develops new leading-edge consumer electronics under Sector 5® and other brands. The Company, by way of its partnership with Google, is offering Chromebook eco-system products for educational organizations, through different B2B (Business-to-Business) and B2C (Business-to-Consumer) sales channels and through Amazon. Sector 5 is based in Alexandria, Virginia, and the Company lists on the OTC Markets Group’s OTCQB.

Sector 5’s emphasis is on providing e-learning products. It has developed new products integrating a seamless wireless charging experience serving the educational, business, and retail markets via easier bulk charging involving charging carts with built-in wireless transmitters.

Last December, Sector 5 announced the addition of its new E2 Chromebook, an HD convertible Chromebook with a touchscreen (1366 x 768 pixels), the Intel Braswell N3060 Processor, as well as a tilting hinge to permit use in tablet and tent mode.

Mr. Roger McKeague, Chief Executive Officer of Sector 5, stated, "Like our Rugged E1, our newest Chromebook is equipped to serve well in schools, colleges, B2B and more! The E2 was developed to have a long-lasting battery for 10 hours of use on a single charge. It has 16-32GB eMMC flash storage and 11.6 inch IPS HD resolution display. There are three USB 3.0 ports, HDMI, micro SD card slot, audio jack, stereo speakers, dual-band WiFi 802.11ac, and Bluetooth 4.0… "

In January 2017, Sector 5 announced that the 2017 Consumer Electronics Show (CES) created the opportunity for the Company to join with its American and Chinese partners to develop a strategy to create skilled jobs in the U.S. as they bring their wireless charging solution to market.

Sector 5 is set to launch its latest education product – the E2 Touchscreen. The Company also has its 65" 4K DLED UHD TV an Ultra Slim TV. The Company says this product is safe and efficient with an eye-catching display and is energy efficient. It features direct LED technology, is of a slim design and includes a stand.

Sector 5, Inc. (SFIV), closed Wednesday's trading session at $2.35, even for the day. The average volume for the last 60 days is 223 and the stock's 52-week low/high is $0.51/$7.95.

Cavitation Technologies, Inc. (CVAT)

ActivePennyStock, PennyStocks24, PennyStockWatchman, UndiscoveredEquities, Beacon Equity Research, MicrocapVoice, MicroStockProfit, Hotstocked, Stock Preacher, Stockwire, TheStockWizards, Stock Stars, CRWEFinance, CRWEWallStreet, DrStockPick, and PennyOmega reported earlier on Cavitation Technologies, Inc. (CVAT), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Established in 2007, Cavitation Technologies, Inc. designs and manufactures state-of-the-art, flow-through, devices and systems. In addition, the Company develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algae oil extraction, alcoholic beverage enhancement, and water treatment. Cavitation Technologies is headquartered in Chatsworth, California. Desmet Ballestra Group, S.A. has been the Company’s strategic partner since 2010.

Cavitation Technologies’ core technology includes the use of hydrodynamic cavitation. Cavitation can be of different origins. These origins include acoustic (normally, ultrasound-induced), hydrodynamic or generated with laser light, accelerated particles, an electrical discharge or steam injection.

Cavitation is a ground-breaking leader in processing liquids, fluidic mixtures, emulsions, and suspended solids. As an add-on to its existing neutralization systems, its patented NanoReactor™ enables refiners to substantially reduce processing costs and environmental impact. This is while also improving yield.

The Company’s technologies can be applied to several other fluid-processing industries that will benefit from increased yields, decreased processing costs, and improved quality. Cavitation has filed patent applications related to edible oil refining, algal oil extraction, renewable fuel production, alcoholic and non-alcoholic beverage processing and enhancement, water treatment and purification, and petroleum upgrading.

Cavitation Technologies has commercialized its patent-pending CTi Nano Neutralization® process. It provides the refiners of edible oils and fats major yield improvements, major cost savings, and environmental benefits.

Desmet Ballestra Group has partnered with Cavitation Technologies to market this pioneering technology around the world to large-scale facilities. Desmet Ballestra Group is the leading global solutions provider for the edible oil and fats and biodiesel industries.

This past February, Cavitation Technologies announced that its strategic partner, Desmet Ballestra Group, sold approximately 100 metric tons per day (MTPD) of the CTi Nano Reactor™ system in Vietnam. This is the first purchase in that nation, and the tenth system sale in Asia.

Last month, Cavitation Technologies announced that GEA Group AG, Westfalia (GEA) entered into a new worldwide technology license, R&D and marketing agreement regarding Cavitation’s patented Nano Reactor™ technology, processes and applications. Under the new agreement, GEA has been granted a worldwide exclusive license to integrate Cavitation Technologies’ patented technology into water treatment application, milk and juice pasteurization, and certain food related processes. The license agreement between Cavitation Technologies and GEA has a three-year term and provides $300,000 per year in advanced license fees to Cavitation Technologies.

Cavitation Technologies, Inc. (CVAT), closed Wednesday's trading session at $0.0387, up 1.84%, on 22,443 volume with 6 trades. The average volume for the last 60 days is 218,948 and the stock's 52-week low/high is $0.0101/$0.059.

Great Basin Scientific, Inc. (GBSN)

Epic Stock Picks, Wolf of Penny Stocks, StreetInsider, Trader Power News, MarketClub Analysis, BUYINS.NET, The Weekly Options Trader, Jason Bond, Promotion Stock Secrets, Stock Beast, StockOodles, InvestorsUnderground, PennyPro, Investing Futures, and Top Stock Picks reported on Great Basin Scientific, Inc. (GBSN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Great Basin Scientific, Inc. is a molecular diagnostics enterprise listed on the NasdaqGS. The Company’s mission is to quickly and accurately diagnose, reduce misdiagnoses, and substantially limit the spread of infectious disease. It commercializes pioneering chip-based technologies. Great Basin’s dedication is to the development of simple, yet robust, sample-to-result technology and products, which provide fast, multiple-pathogen diagnoses of infectious diseases. Great Basin Scientific is headquartered in Salt Lake City, Utah.

Great Basin Scientific’s sample-to-result molecular diagnostics are fully automated with few hands-on steps. Depending on the target of interest, results are in two hours or less. In addition, sample-to-result molecular diagnostics feature on-demand testing. There is no upfront analyzer cost. Furthermore, sample-to-result molecular diagnostics multiplexes up to 64 distinct targets in a single assay for more answers.

The Company’s diagnostic system empowers health providers with accurate and timely information. This information is for diagnosing infectious disease. This allows health providers to appropriately treat patients to improve outcomes and support antimicrobial stewardship. This results in shorter hospital stays and money saved.

Great Basin’s diagnostic system utilizes an integrated disposable cartridge containing all essential reagents. Moreover, it uses an inexpensive bench-top analyzer. This analyzer executes the assay, interprets the results, and provides electronic output to the clinician. The user-friendly tests deliver more diagnostic data per sample.

Great Basin Scientific has four commercially available assays: The Staph ID/R Blood Culture Panel, Shiga Toxin Direct Test, Group B Streptococcus (GBS) Test, and the Toxigenic Clostridium difficile (C. diff) Test. The Company also has five additional tests and panels in the development phase: Nasal S. aureus Pre-Screen, Candida Blood Infections Panel, Stool Bacterial Pathogens Panel, CT/NG Test, and Bordetella Direct Test.

In March, Great Basin Scientific reported operating results for Q4 and full year ended December 31, 2016. Q4 Revenue rose 39 percent year-over-year; 2016 revenues grew 42 percent. The Company’s Quarterly Gross Margin improved 42 basis points over Q3 to its best level of the year. Also, the percentage of customers using more than one assay rose 17 percent quarter-over-quarter and 81 percent year-over-year.

This week, Great Basin Scientific announced that it received U.S. Food & Drug Administration (FDA) clearance for its Bordetella Direct Test, following a 510(k) submission on February 1, 2017. Great Basin received notification of clearance from the FDA on Friday, March 31, about 57 days from submission. The Bordetella Direct Test expands the Company’s menu of FDA cleared assays to five.

Great Basin Scientific, Inc. (GBSN), closed Wednesday's trading session at $0.0048, down 32.39%, on 724,879,843 volume with 4,567 trades. The average volume for the last 60 days is 96,948,550 and the stock's 52-week low/high is $0.0007/$485.60.

DXI Energy, Inc. (DXIEF)

We are highlighting DXI Energy, Inc. (DXIEF) today, here at the QualityStocks Daily Newsletter.

DXI Energy, Inc. is a tactical acquisitor and developer of strategic energy resources. The Company is an upstream oil and gas exploration and production enterprise. DXI Energy operates in Colorado’s Piceance Basin and in the Peace River Arch area in British Columbia (BC). DXI Energy has offices in Calgary, Alberta and Vancouver, BC.

Concerning its project areas, in the Piceance Basin (25,684 net acres) in northwest Colorado, DXI Energy has its Kokopelli project with 12 producing wells with extensive in place infrastructure to supplement future development as product prices dictate. Its land holdings in the Piceance Basin highlight potential long-term regional resource value. This is as utilities develop sources of natural gas. For Kokopelli, DXI Energy retains a 25 percent Working Interest (WI) in 2200 acres.

Additionally, DXI has its Roan Creek project (West Piceance Hi-Pressure Mancos/Niobrara Gas). This project is 1960 net acres, 100 percent WI, with potential development of 8-10 high pressure Mancos/Niobrara 8200’ vertical/Hz wells.

Regarding the Piceance Basin in Colorado, it is over100 miles long. It has an average width of over 60 miles, covering an area of more than 7,100 square miles. It contains reserves of coal, natural gas, as well as oil shale.

The Woodrush Project, northeastern BC, spans 14,444 net acres with 14 wells (3 oil and gas, 10 natural gas and one injector). DXI Energy is the operator. The Company owns 99 percent of the Project, which is currently producing 315 BOEPD (30 percent oil).

DXI Energy has a multi-phase plan to expand production and landholdings at the Woodrush Project. It is implementing a remedial program at Woodrush designed to improve daily oil production to the 200 BOPD range. Moreover, DXI, given continued improvement in the commodity markets, intends to drill 3 new "lower risk" exploratory wells at the Woodrush Project to test for Halfway oil and Gething gas on current and associated new leaseholds. The projection is that this program will boost daily production by an average 450 BOEPD on a fully risked basis.

Last month, DXI Energy announced corrections to the "Revenue" and "Royalties" dollar amounts included in the Q4 and Fiscal 2016 financial results press release announcement distributed to the public on March 22, 2017.

The revised numbers are: Revenue for the three months ended December 31, 2016 were 954 (CA$ thousands) versus 2,768 (CA$ thousands) for the three months ended December 31, 2015. Royalties for the three months ended December 31, 2016 were 127 (CA$ thousands) versus 517 (CA$ thousands) for the three months ended December 31, 2015.

For the twelve months ended December 31, 2016, Revenues was 4,808 (CA$ thousands) versus 8,579 (CA$ thousands) for the twelve months ended December 31, 2015. Royalties for twelve months ended December 31, 2016 were 735 (CA$ thousands) versus 1,483 (CA$ thousands) for the twelve months ended December 31, 2015.

DXI Energy, Inc. (DXIEF), closed Wednesday's trading session at $0.05, down 13.64%, on 6,798 volume with 7 trades. The average volume for the last 60 days is 41,281 and the stock's 52-week low/high is $0.032/$0.1392.

Talon International, Inc. (TALN)

Wall Street Mover, TopPennyStockMovers, Greenbackers, Wallstreetlivechat, OtcWizard, PennyStocks24, Liquid Tycoon, Penny Pick Finders, Penny Stock MoneyTrain, Penny Stock Pick Alert, Penny Stock Pick Report, PennyStockProphet, SecretStockPromo, StockOnion, Super Hot Penny Stocks, Super Nova Stock Picks, WePickPennyStocks, and Winning Penny Stock Picks reported previously on Talon International, Inc. (TALN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Talon International, Inc. is a foremost global supplier of zippers, apparel fasteners, trim, and stretch technology products. The Company supplies these products to manufacturers of fashion apparel, specialty retailers, mass merchandisers, brand licensees, as well as major retailers around the world. Established in 1893, Talon is the world’s original zipper brand.

Talon International has its corporate head office in Los Angeles, California. Moreover, the Company has offices and facilities across the U.S., and in the United Kingdom (UK), Hong Kong, China, Vietnam, India, Indonesia and Bangladesh. The Company lists on the OTC Markets Group’s OTCQB.

Talon was the inventor of the zipper. It proceeded to pioneer a number of innovations customary in zippers today. Talon’s TekFit® is its newest division. TekFit® has exclusive rights to advanced fabric technologies that facilitate the addition of mechanical stretch into most standard fabrics.

Talon develops, manufactures and distributes custom zippers exclusively under its Talon® brand (The World's Original Zipper Since 1893). In addition, it designs, develops, manufactures, and distributes complete apparel trim solutions and products; and provides stretch technology for specialty waistbands, shirt collars, and other items all under its trademark and globally renowned brands, Talon®, and TekFit®.

Last week, Talon International reported its financial results for Q4 and the fiscal year ended December 31, 2016. The Company stated that Revenues were flat for 2016 in comparison to 2015 as Trim sales continued to rise while Zipper sales declined. Trim Revenues posted a 13 percent increase in comparison to the prior year.

Talon International’s overall Gross Profit rose 8.3 percent, or $1.3 million versus 2015. Gross Margins improved to 36.5 percent in 2016 from 33.7 percent the year prior because of a more favorable product mix and operational cost improvements. The Company’s Income from Operations grew $1.3 million over 2015.

Net Loss for the quarter ended December 31, 2016 was $33,000 or $0.00 per share versus net income of $312,000 or $0.00 per share for the quarter ended December 31, 2015. Net Income for the year ended December 31, 2016 was $1.0 million or $0.01 per share versus $511,000 or $0.01 per share for the year ended December 31, 2015.

Talon International, Inc. (TALN), closed Wednesday's trading session at $0.122, even for the day. The average volume for the last 60 days is 3,241 and the stock's 52-week low/high is $0.06/$0.178.

graphic

The QualityStocks
Company Corner

graphic
graphic

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $1.25, off by 0.40%, on 88,003 volume with 88 trades. The stock’s average daily volume over the past 60 days is 177,175 and its 52-week low/high is $0.12/$2.75.

ChineseInvestors.com today announced that it will attend the 'Invest 2017' exhibition in Stuttgart, Germany which will take place on April 7-8, 2017. Invest 2017 is the leading trade fair and congress for finance and investment in Germany, and provides CIIX the opportunity to introduce its media and nutritional hemp companies, http://www.ChineseFN.com and http://www.ChineseCBDoil.com to German investors.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

ChineseInvestors.com to Attend 'Invest 2017' Exhibition in Stuttgart, Germany

ChineseInvestors.com Announces Investment in Breakwater MB, LLC a Cannabis-Focused Investment and Consulting Company

Alan Klitenic, Director of Investor Relations for ChineseInvestors.com, Discusses Recent CIIX News and Industry Trends in a New Audio Interview with SmallCapVoice.com

India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.5363, off by 6.16%, on 975,194 volume with 1,890 trades. The stock’s average daily volume over the past 60 days is 337,784, and its 52-week low/high is $0.19/$0.80.

India Globalization Capital, Inc. announces today that it has sold its ten percent holding in Brilliant Hallmark for a consideration of four million shares of IGC. As a result of this transaction, 4,000,000 IGC common shares previously issued to Brilliant Hallmark, on August 4, 2016, will be returned and retired, thereby reducing the outstanding IGC shares from approximately 28,272,667 million before the sale to approximately 24,272,667 million after the sale. In addition, the Brilliant Hallmark investment will be removed from the IGC balance sheet with an associated reduction of approximately $1.88 million. The Company does not expect to record a gain or loss from this transaction.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

IGC Sells Malaysian Hotel Investment Interest, Consolidates Corporate Focus on Development of Cannabis-Based Combination Therapies

IGC Files Patent for Cannabis-based Combination Therapy for Treatment of Eating Disorders

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) CEO Featured in Benzinga Article

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.5692, up 35.69%, on 4,249,739 volume with 1,678 trades. The stock’s average daily volume over the past 60 days is 894,626, and its 52-week low/high is $0.05/$0.437.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media

InMed's Exceptional Management Team Executes Ambitious Plan -- CFN Media

NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use

CD International Enterprises, Inc. (CDII)

The QualityStocks Daily Newsletter would like to spotlight CD International Enterprises, Inc. (CDII). Today, CD International Enterprises, Inc. closed trading at $0.0285, up 33.18%, on 1,074,513 volume with 90 trades. The stock’s average daily volume over the past 60 days is 659,037 and its 52-week low/high is $0.0001/$52.00.

CD International Enterprises, Inc. (CDII) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.CD International Enterprises, Inc., CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

CD International Enterprises, Inc. Blog

CD International Enterprises, Inc. News:

CD International Enterprises Enters Agreement to Distribute Cannabidiol (CBD) in the United States

CD International Enterprises Enters Consulting Agreement with Zhangjianjie Shengshi Agricultural Development Company, Limited

CD International Enterprises Enters Corporation Agreement With Everbright Investment and Construction Company, Limited

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.3599, up 10.74%, on 376,429 volume with 155 trades. The stock’s average daily volume over the past 60 days is 118,983 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

NetworkNewsWire Announces Publication on Solutions for the Health Care Industry's Data Processing Needs

NetworkNewsWire Announces Publication of Discussion on the Value of IT & Big Data Analytics for the Health Care Industry

NetworkNewsWire Releases Exclusive Audio Interview with ORHub, Inc. (ORHB)

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Trader Power News
(PLUG) +73.08%

2.

StockMarketWatch
(TGC) +50.00%

3.

BUYINS.NET
(CALI) +41.75%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251